Dr Jack Scannell has unusually broad experience relevant to Unify; in drug discovery, in biopharma investment, in R&D productivity, and in neuroscience. He led Discovery Biology at E-Therapeutics PLC, an Oxford-based biotech firm. He was Co-Head of European Pharmaceuticals and Biotech at UBS Investment Bank and Head of European Healthcare at Sanford Bernstein.
He has a PhD in Neuroscience from Oxford University and a Bachelor’s degree in Medical Sciences from Cambridge University. He is perhaps best known for his work on biopharma R&D productivity.
Prof Laura Dugan is a neuroscientist and physician. Her work on neurodegenerative diseases and aging – related disorders forms the basis of Unify’s scientific portfolio and business assets. It was built on ~$40m of competitive academic grant funding.
Dugan is the Abram C. Shmerling chair in Alzheimer’s and Geriatric Medicine at Vanderbilt University in Nashville, Tennessee. She was tenured faculty at Washington University in St. Louis, and at the University of California, San Diego, She trained at two of the world’s premier scientific institutions; MIT and Stanford.
Prof Sir Marc Feldmann invented and developed the first successful monoclonal antibody therapy, anti-TNF, in his pioneering work with Remicade in the early 1990s. Remicade went on to sell over $7bn per year and the anti-TNFs became the World’s best selling drug class.
Feldmann has been heavily involved in both academic and commercial R&D ever since; from discovery through to life-cycle management. He came across Prof. Dugan’s research around 2014 and saw it shared important features with the anti-TNFs. He and Dugan founded Unify Pharmaceuticals in 2018. Feldmann is Unify’s major investor.
Dr Chakraborty is an experienced synthetic organic chemist with decades of experience designing, synthesizing, and testing novel biologically active compounds.
He has occupied a number of positions leveraging his expertise in the agricultural sciences sphere, including a seven-year period as a Senior Scientist in the Pesticide Division of EID Parry, a Chennai-based sugar producer with a market capitalization of over $30 B USD.
Returning to academia, he worked at National Tsing Hua University in Taiwan aiding in the synthesis of multifunctional dihydrofurans, and the total synthesis of Tamsulosin hydrochloride, a prostatic hypertrophy drug. Between 2004 and 2016, he moved to the US in the capacity of Senior Research Scientist at Carnegie Mellon University, in Pittsburgh. He has worked in Prof Dugan’s research group since 2016.
Dr Chakraborty was educated at Bidhan Chandra Krishi Viswavidyalaya, in West Bengal, India, where he attained an MSc in agricultural chemistry in 1987, and a PhD in the same subject in 1993. His name features on eight patents.
Chas Bountra is the Pro-Vice Chancellor for Innovation and Professor of Translational Medicine at Oxford University. He is also the Director of the Centre for Medicines Discovery. From 2008 to 2020 he Directed the Structural Genomics Consortium at Oxford; a leading international partnership between the drug industry and the public sector.
Before returning to Oxford, Bountra was Head of Biology at GlaxoSmithKline where he was involved in the identification of more than 40 clinical candidates across a range of therapy areas. More than 20 candidates progressed into human trials and more than five moved into late stage development.
Ozan is a VC with a hands-on approach, involved with several companies as CFO and a board member. He brings a wealth of knowledge and experience to the Unify team as a former investment banker with in-depth capital markets expertise.
Throughout his career, he has specialized in helping companies in defining their corporate strategy, and execute corporate transactions such as M&As and IPOs.
Recently, as CFO and board member, Ozan was overseeing the complex merger and financing of three biotech companies, which resulted in the formation of 180 Life Sciences; a clinical stage company going public on NASDAQ.
He is also the CFO of Enosi Life Sciences, a company focused on autoimmune diseases and cancer.
Ozan was previously VP of Investment Banking at a leading Canadian independent investment bank, where he co-founded the origination department which focused on small and mid-cap financing and advisory mandates. He advised private and public companies on M&A deals and was the lead banker on 30+ financings, raising approximately $400 million.
He holds an Economics and Finance degree from McGill University and is a CFA Charterholder.
Dennis Choi is a pioneer in nervous system injury. He is Professor of Neurology at Stony Brook. He sits on the scientific advisory boards of several organisations, including the Cure Alzheimer’s Fund. He was the Director of the Brain Science Institute at the Korea Institute of Science and Technology and the EVP for Neuroscience at Merck Research Labs. He was President of Society for Neuroscience and the Vice President of the American Neurological Association.
Dr Choi received his MD from the Harvard-MIT Health Sciences and Technology Program, and subsequently went on to receive a PhD in pharmacology and neurology, also from Harvard.
Lawrence Steinman is the George A. Zimmermann Endowed Chair in the Neurology Department of Stanford University. He has experience in medical businesses, founding Neurocrine Biosciences, Tolerion, Transparency Life Sciences and Atreca. He held a fellowship in chemical immunology at the Weizman Institute. He served as the Chair of the Interdepartmental Program in Immunology at Stanford between 2003 and 2011. He received the Frederich Sasse Award in 1994, the John Dystel Prize in 2004, the Charcot Prize in 2011, and the Cerami Prize in 2015. Steinman studied at Dartmouth and Harvard.